Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Long-Term Debt Issuances (2016 - 2025)

Historic Long-Term Debt Issuances for Ernexa Therapeutics (ERNA) over the last 8 years, with Q1 2025 value amounting to $2.2 million.

  • Ernexa Therapeutics' Long-Term Debt Issuances rose 6014.23% to $2.2 million in Q1 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 8072.81%. This contributed to the annual value of $3.9 million for FY2024, which is 7644.67% down from last year.
  • As of Q1 2025, Ernexa Therapeutics' Long-Term Debt Issuances stood at $2.2 million, which was up 6014.23% from $2.5 million recorded in Q3 2024.
  • Ernexa Therapeutics' Long-Term Debt Issuances' 5-year high stood at $7.8 million during Q4 2023, with a 5-year trough of $1.4 million in Q1 2024.
  • Over the past 3 years, Ernexa Therapeutics' median Long-Term Debt Issuances value was $2.4 million (recorded in 2024), while the average stood at $3.5 million.
  • Examining YoY changes over the last 5 years, Ernexa Therapeutics' Long-Term Debt Issuances showed a top increase of 6014.23% in 2025 and a maximum decrease of 6014.23% in 2025.
  • Ernexa Therapeutics' Long-Term Debt Issuances (Quarter) stood at $7.8 million in 2023, then tumbled by 68.13% to $2.5 million in 2024, then fell by 9.35% to $2.2 million in 2025.
  • Its Long-Term Debt Issuances was $2.2 million in Q1 2025, compared to $2.5 million in Q3 2024 and $1.4 million in Q1 2024.